Leerink analyst Daniel Clark initiated coverage of Idexx Laboratories (IDXX) with an Outperform rating and $500 price target The firm notes Idexx Laboratories is the dominant player in the veterinarian testing space and has been the best growth story in animal health. The company has benefited from a steady increase in diagnostic testing in pets, complemented by new product launches that have been well-received by veterinarians. Aided by its proprietary MEDACorp survey work, Leerink sees a continued runway of growth for Idexx. Although vet visit volumes are outside the company’s control, the firm does note that its survey respondents expect a pickup in volumes, which helps it get comfortable modeling above-consensus revenue and adjusted EPS growth in 2025.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IDXX:
- IDEXX Laboratories Announces CFO Transition Plan
- Idexx Laboratories backs FY24 EPS view $10.37-$10.53, consensus $10.73
- Idexx Laboratories CFO Brian McKeon to retire, Andrew Emerson to succeed
- Idexx Laboratories Announces CEO Jonathan Ayers’ Resignation
- Idexx Laboratories price target lowered to $435 from $520 at Piper Sandler
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
